Emergent BioSolutions anthrax vaccine gets boost - Phoenix Business Journal:

stages-paddocks.blogspot.com
The Rockville-based company’s BioThrax has been granteds a shelf life extension from the from its current thres yearsto four. Under its contract with the Department of Healtgh andHuman Services, the extensioh triggers a milestone payment of $30 milliom for doses of the vaccine alreadg delivered to the Strategic National Stockpile. Emergenrt expects to record that payment as revenusethis quarter. The shelf life extension also allows Emergent to charge more for futurwe doses of the vaccine delivered tothe government’s That could raise the valuew of the contract to as much as $405 million over the next severalo years.
Last year, the FDA approved a reduceed vaccination schedule to five Emergent continues research that could lead to a furtherf reduction in the number ofdoses required, as well as the vaccine’se use to treat patients after beingf exposed to Anthrax, not just as a pre-exposurew vaccine. Emergent has supplied the government’zs stockpile with 33 million doses of BioThradso far. It is contracted to continue addinb to stockpiles throughlate 2011. BioThrax has been used to vaccinat e more than 2 million military personneo since the government first started buying the vaccinein 1998. Emergenr stock (NYSE: EBS) was up 90 cents to $14.63 per shar in afternoon trading.